All In Biotech

Drug Trial Radar · NCT07163143

Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding (RADIO-TB Trial)

Optimal Treatment Duration for Radiographically Apparent, Bacteriologically Unconfirmed TB, Identified Through Active Case Finding

Last checked: Nov 20, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 784 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

784

Planned (sponsor's estimate)

Start

Oct 12, 2026

Primary completion

Nov 2028

Study completion Apr 2029

Sponsor

Lead sponsor
University College, LondonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National University of Medical Sciences, Pakistan; Aurum Institute; Biomedical Research and Training Institute, Zimbabwe; Foundation for Innovative New Diagnostics, Switzerland; KTH Royal Institute of Technology; London School of Hygiene and Tropical Medicine; Wits Health Consortium (Pty) Ltd
First posted
Sep 9, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 16 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

People living in high TB burden communities who undergo active case finding for TB may have chest X-ray changes suggestive of TB but their sputum test can be negative for the TB bacteria or they are unable to provide a sputum sample. This means they have bacteriologically unconfirmed TB. These individuals often have minimal or no symptoms and face uncertainty in clinical management-either receiving full 24-weeks TB treatment or often being discharged without treatment, risking loss to follow-up. The RADIO-TB trial aims to address the following main questions in relation to people with bacteriologically unconfirmed TB. 1. What is the risk of progression if treatment is not immediately started but there is close and careful follow-up over 78 weeks? 2. If treatment is started immediately what is the shortest duration of TB treatment that is as effective as the standard 24-week TB treatment? 3. Are there better tests to confirm TB than the current routinely used, sputum-based tests? 4. What is the cost effectiveness of different treatment strategies and what might the impact on transmission be within communities? Participants in the trial will be randomized into six groups: five receiving immediate standard TB treatment of varying durations (8 to 24 weeks), and one receiving deferred treatment with close monitoring. Deferred treatment will be initiated only if clinical deterioration occurs or TB is later confirmed. Participants will be closely followed for 78 weeks with at least 11 clinic visits.

Conditions

  • Tuberculosis (TB)

Interventions

  • Isoniazid (H)Drug

    H, weight based, 150-375mg

  • Rifampicin (R)Drug

    R, weight based, 300-750mg

  • Pyrazinamide (Z)Drug

    Z, weight based, 800-2000mg

  • Ethambutol (E)Drug

    E weight based, 550-1375mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of participants with an unfavourable TB outcomeTime frame: Over 78 weeks post-randomisation

Locations

4 sites in 3 countries. Site status is shown where the registry gives one.

  • National University of Medical Sciences

    Islamabad, Pakistan · Not yet recruiting

  • Clinical HIV Research Unit, Wits Health Consortium

    Johannesburg, South Africa · Not yet recruiting

  • The Aurum Institute

    Johannesburg, South Africa · Not yet recruiting

  • Bulawayo City Health

    Bulawayo, Zimbabwe · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.